EQ

Equillium is a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory disorders with high unmet medical need. The company's lead product candidate, itolizumab, is a first-in-class anti-CD6 monoclonal antibody being evaluated for acute graft-versus-host disease and other autoimmune conditions. Equillium focuses on repurposing and developing novel immunomodulatory therapies. The company's approach targets specific immune pathways to selectively modulate aberrant immune responses while preserving normal immune function.